Filters

Ralf Schröder, Luzheng Xue, Viktoria Konya, Lene Martini, Nora Kampitsch, Jennifer L Whistler, Trond Ulven, Akos Heinemann, Roy Pettipher, Evi Kostenis

PloS one 2012;7(3):e33329

Free Full Text

Abstract

Niacin and laropiprant.

S Sanyal, J T Kuvin, R H Karas

Drugs of today (Barcelona, Spain : 1998) 2010;46(6):371-8

Full Text

Abstract

Results: 1 – 15 / 77

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Receptors, Prostaglandin""[mesh_terms]

Ca(2+) signals evoked by histamine H1 receptors are attenuated by activation of prostaglandin EP2 and EP4 receptors in human aortic smooth muscle cells.

Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.

NF-κB-dependent IL-8 induction by prostaglandin E(2) receptors EP(1) and EP(4).

The complex role of prostaglandin E-EP receptor signaling in wound healing.

The role of cyclooxygenases and prostanoid receptorsin furosemide-like salt losing tubulopathy: the hyperprostaglandin E syndrome.

Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.

Intermolecular cross-talk between the prostaglandin E2 receptor (EP)3 of subtype and thromboxane A(2) receptor signalling in human erythroleukaemic cells.

D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells.

Involvement of non-conserved residues important for PGE2 binding to the constrained EP3 eLP2 using NMR and site-directed mutagenesis.

Prostaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4.

Colonic Saturated Fatty Acid Concentrations and Expression of COX-1, but not Diet, Predict Prostaglandin E2 in Normal Human Colon Tissue.

Discovery and Functional Validation of EP3 Receptor Ligands with Therapeutic Potential in Cardiovascular Disease.

Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.

PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2.

Niacin and laropiprant.

Results for
""Receptors, Prostaglandin""[mesh_terms]